TOP HEADLINES

Featured Story

Novo Nordisk bets another $130M on diabetes R&D with new Danish hub

Novo Nordisk has broken ground on a new R&D shop in its native Denmark, plotting a $130 million project that will expand its wide footprint in diabetes research.

Clarus and Frazier back a 'backyard' biotech team with $26.5M for epigenetics R&D

The band behind FerroKin BioSciences, a pioneer of the virtual biotech model, has gotten back together to take a stab at epigenetics, raising $26.5 million from some A-list investors to develop new treatments for orphan diseases.

Daiichi Sankyo's new a-fib drug heads toward FDA approval and a crowded market

A panel of FDA advisers voted in favor of approving Daiichi Sankyo's irregular heartbeat treatment edoxaban, heralding its ability to break up blood clots and improving the company's odds of finally launching the drug in the U.S.

Impax cans 25% of its R&D staff in a cost-cutting gambit

Impax Laboratories is slashing its R&D payroll and moving away from early-stage research, a move designed to save cash in the midst of a costly transition.

Novartis sets sights on Philly amid a sweeping CAR-T collaboration

Novartis has leased a sizable outpost in the Philadelphia suburbs, according to a local report, settling into the area as it works with University of Pennsylvania researchers on a promising new approach to treating cancer.

MORE NEWS